| Scientific Overview |
| |
| NAD+ (nicotinamide adenine dinucleotide) is a fundamental metabolic coenzyme central to mitochondrial bioenergetics, redox balance, DNA repair, and epigenetic regulation. Age-related NAD+ decline is associated with mitochondrial dysfunction, impaired metabolic flexibility, genomic instability, and chronic low-grade inflammation (“inflammaging”). In clinical-functional medicine, NAD+ restoration is positioned as a strategy to support cellular resilience, metabolic efficiency, and healthy aging. |
| Mechanism of Action |
| |
| NAD+ functions as: |
| |
• A redox cofactor in glycolysis, TCA cycle, and oxidative phosphorylation
• A substrate for sirtuins (SIRT1–7), influencing mitochondrial biogenesis and stress resistance
• A cofactor for PARPs, essential for DNA repair
• A regulator of CD38 activity, affecting immune-metabolic signaling |
| |
| Improved NAD+ availability enhances mitochondrial ATP production, supports genomic stability, and may improve metabolic adaptability under physiologic stress. |
| Biological and Clinical Effects |
| |
| Preclinical and translational studies demonstrate improved mitochondrial respiration and electron transport chain efficiency, reduced oxidative stress and inflammatory signaling, enhanced insulin sensitivity and metabolic flexibility, and neuroprotective signaling pathways. In clinical-functional practice, NAD+ is often integrated into protocols addressing fatigue syndromes, metabolic dysregulation, cognitive support, and recovery optimization. |
| Time of Use / Treatment Duration |
| |
| Metabolic optimization programs: 4–8 week structured cycles. Neurocognitive or fatigue protocols: 8–12 weeks with reassessment. Longevity-support programs: cyclic administration (e.g., 4–6 weeks on, 4 weeks off). Long-term continuous use should be guided by laboratory monitoring and clinical response. |
| Safety, Tolerability, and Precautions |
| |
| Reported effects may include transient nausea, flushing, and injection-site discomfort. Caution is advised in pregnancy, lactation, and advanced hepatic dysfunction. |
|
Detailed References
| Verdin E. (2015). NAD+ in aging, metabolism, and neurodegeneration. Science, 350(6265):1208–1213. |
| |
| Yoshino J, et al. (2018). NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metabolism, 27(3):513–528. |
| |
| Canto C, et al. (2012). The NAD+ precursor nicotinamide riboside enhances oxidative metabolism. Cell Metabolism, 15(6):838–847. |
| |
| Rajman L, et al. (2018). Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metabolism, 27(3):529–547. |
| |
| Martens CR, et al. (2018). Chronic nicotinamide riboside supplementation is well tolerated and elevates NAD+ in healthy adults. Nature Communications, 9:1286. |
| |
| LaValle J. The Complete Guide to Peptides. Clinical-functional framework for mitochondrial optimization and metabolic resilience. |
| |
|
|
|
Posology (Clinical Practice–Oriented)
Intravenous protocols (clinical settings):
• 250 mg–1000 mg per infusion
• 1–3 times weekly (loading phase)
• Infusion over 1.5–4 hours to reduce adverse effects
Subcutaneous protocols:
• 100–300 mg per injection, 2–5 times per week
Biomarker monitoring may include fasting glucose and insulin, hs-CRP, and liver enzymes.
|
|
Clinical Practice Framing
NAD+ is best positioned as a mitochondrial optimization strategy, adjunctive to nutrition, sleep restoration, resistance training, and oxidative stress management. It is not a stand-alone intervention but part of a comprehensive metabolic resilience program.
|
|
Reviews
There are no reviews yet.